Key Points
- UE Lifesciences' iBreastExam device uses pressure sensing technology to identify breast tissue abnormalities.
- The portable device enables early detection and follow-up care in primary care settings and communities worldwide.
- Over 2,00,000 women have been screened with iBreastExam in Goa, detecting 3,600 abnormalities and 93 cancer cases.
How iBreastExam Works
UE Lifesciences' iBreastExam device is a portable, handheld device that uses pressure sensing technology to identify breast tissue abnormalities. This enables early detection and follow-up care in primary care settings and communities worldwide.
The device is battery-operated and does not require an internet connection, making it accessible to remote regions. Trained health workers use the device to conduct breast screenings, which can help detect abnormalities that may have been missed in a routine clinical examination.
At a Glance
| Main Company | UE Lifesciences Developer of iBreastExam |
| Device | iBreastExam Portable breast cancer screening device |
| Technology | Pressure sensing Identifies breast tissue abnormalities |
| Country | India Headquartered and has manufacturing unit |
| Country | US Regulatory approvals secured |
| Country | Malaysia Subsidiary location |
Behind the Scenes of UE Lifesciences' Efforts
Behind the Scenes of UE Lifesciences' Efforts
UE Lifesciences was founded by Mihir Shah, Bhaumik Sanghvi, and Dr. Matthew Campisi, and is backed by Biocon's Kiran Mazumdar-Shaw, among others.
The company has secured regulatory approvals in over 12 countries and has subsidiaries in India and Malaysia, as well as a manufacturing unit in Mumbai.
UE Lifesciences is currently scaling up the availability of iBreastExam through distribution tie-ups with various companies in India, West Asia, Africa, and Southeast Asia.
What This Means for Women's Health
What This Means for Women's Health
Women in remote regions can now access early detection and follow-up care for breast cancer through the use of iBreastExam.
UE Lifesciences is also developing two more products for early screening, one for cervical cancer and the other for oral health.
Healthcare providers and policymakers can work together to increase access to iBreastExam and other early detection tools in underserved communities.
Comments 0